Transplantation tolerance has become an experimental reality, yet the bridge from the laboratory to the clinic has only begun to be traversed. Many obstacles remain before patients will be able to benefit from the extraordinary advances in transplant immunology. This paper presents an overview of issues that will likely affect the clinical development of broadly applicable tolerance regimens. Biologic issues as well as issues related to drug development are discussed.